The Enigma of Β 2 -Adrenergic Receptor G I Signaling in the Heart
Weizhong Zhu,Xiaokun Zeng,Ming Zheng,Rui-Ping Xiao
DOI: https://doi.org/10.1161/01.res.0000184615.56822.bd
IF: 23.213
2005-01-01
Circulation Research
Abstract:HomeCirculation ResearchVol. 97, No. 6The Enigma of β2-Adrenergic Receptor Gi Signaling in the Heart Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBThe Enigma of β2-Adrenergic Receptor Gi Signaling in the HeartThe Good, the Bad, and the Ugly Weizhong Zhu, Xiaokun Zeng, Ming Zheng and Rui-Ping Xiao Weizhong ZhuWeizhong Zhu From the Laboratory of Cardiovascular Science (W.Z., X.Z., R.-P.X.), National Institute of Aging, National Institutes of Health, Baltimore, Md; and The Institute of Molecular Medicine (M.Z., R.-P.X.), Peking University, Beijing, China. Search for more papers by this author , Xiaokun ZengXiaokun Zeng From the Laboratory of Cardiovascular Science (W.Z., X.Z., R.-P.X.), National Institute of Aging, National Institutes of Health, Baltimore, Md; and The Institute of Molecular Medicine (M.Z., R.-P.X.), Peking University, Beijing, China. Search for more papers by this author , Ming ZhengMing Zheng From the Laboratory of Cardiovascular Science (W.Z., X.Z., R.-P.X.), National Institute of Aging, National Institutes of Health, Baltimore, Md; and The Institute of Molecular Medicine (M.Z., R.-P.X.), Peking University, Beijing, China. Search for more papers by this author and Rui-Ping XiaoRui-Ping Xiao From the Laboratory of Cardiovascular Science (W.Z., X.Z., R.-P.X.), National Institute of Aging, National Institutes of Health, Baltimore, Md; and The Institute of Molecular Medicine (M.Z., R.-P.X.), Peking University, Beijing, China. Search for more papers by this author Originally published16 Sep 2005https://doi.org/10.1161/01.RES.0000184615.56822.bdCirculation Research. 2005;97:507–509Four decades ago, it was thought that the cardiac β-adrenergic receptor (AR) was β1AR, the vascular/bronchial counterpart was β2AR, and that β2AR was either nonexistent or nonfunctional in myocardium.1 In the heart, stimulation of β1AR leads to PKA-dependent phosphorylation of a set of Ca2+ regulatory proteins, including sarcolemmal L-type Ca2+ channels, sarcoplasmic reticulum (SR) Ca2+-release channels (ryanodine receptors), SR Ca2+-ATPase (SERCA) and its regulator phospholamban (PLB), and some myofilament proteins, resulting in positive inotropic, lusitropic, and chronotropic effects. However, over the past decade, compelling evidence has shown that the β2AR subtype is expressed in the heart and its signaling and functionalities markedly differ from those evoked by the closely related βAR subtype, the β1AR. Unlike β1AR, β2AR couples dually to Gs and Gi proteins; the β2AR-Gi signaling pathway plays a crucial role in cardioprotection against apoptotic death of myocytes in culture and in vivo (the “good”), while attenuating the β2AR-Gs-mediated inotropic response (the “bad”) (Figure).2 Now, in the current issue of Circulation Research, He et al revealed one “ugly” facet of the β2AR-Gi signaling in a canine heart failure model.3 They demonstrated that in the failing heart, activation of β2AR dampens the ability of β1AR, the primary cardiac subtype, to stimulate ICa,L, thus resulting in an overall dysfunction of βAR inotropic response in the failing heart (Figure).3 Specifically, the effect of βAR stimulation with a nonselective agonist, isoproterenol (ISO), on ICa,L is strikingly diminished in cardiomyocytes from canine failing heart, but can be revived by disruption of Gi function with pertussis toxin (PTX) or β2AR blockade with ICI 118 551.3 These findings highlight that an alteration in the status of the β2AR-Gi coupling can dictate the overall outcome of cardiac βAR signaling under some pathological circumstances. Thus, this enigmatic, multifaceted β2AR-Gi signaling pathway might bear important pathogenic and therapeutic implications. Download figureDownload PowerPointCross Inhibition of β1AR-mediated activation of L-type Ca2+ currents (ICa,L) and positive inotropic effect by enhanced β2AR-Gi signaling in the failing heart. The β2AR-Gi signaling also protects cardiomyocytes against β1AR-mediated apoptosis and maladaptive remodeling via suppressing PKA-independent stimulation of ICa,L and CaMKII (PTX indicates pertussis toxin; PKA, protein kinase A; CaMKII, Ca2+/calmodulin-dependent protein kinase II). In addition, in the normal heart but not the failing heart, heterodimerization of β1AR and β2AR optimizes β-adrenergic modulation of cardiac contractility likely via reducing β2AR-Gi coupling.The “Good”: Cardioprotection Induced by Sustained β2AR StimulationA large body of evidence gleaned from pharmacological and mouse genetic studies has revealed opposing contributions of sustained β1AR and β2AR stimulation in regulating the fate of cardiomyocytes. Whereas sustained β1AR stimulation promotes apoptotic death of cardiomyocytes, sustained stimulation of β2AR protects myocytes against a wide range of apoptotic insults. For instance, agonist-induced β2AR stimulation prevents catecholamine-, hypoxia-, or reactive oxygen species (ROS)-induced apoptotic death in both neonatal and adult rat cardiomyocytes.4–6 Moreover, in adult mice lacking the native β2AR, stimulation of the native β1AR by catecholamine causes overtly exaggerated cardiomyopathy, myocyte apoptosis, and more severe heart failure relative to wild-type control animals.7 In contrast, selective activation of β2AR by fenoterol for 8 weeks exerts a clear antiapoptotic effect and improves cardiac performance in a myocardial infarction–induced rat heart failure model.8 These in vivo studies have provided evidence that β2AR stimulation exerts a cardiac protective effect in response to elevated circulating catecholamine levels or myocardial infarction.The cardiac protective effect of persistent β2AR signaling is largely mediated by β2AR-Gi coupling, which, in turn, activates a cell survival pathway sequentially involving Giβγ, PI3K, and Akt. First, β2AR blockade enhances β1AR-induced apoptosis in cultured adult rat myocytes in a PTX-sensitive manner, suggesting the β2AR protective effect is Gi-dependent.4 Second, β2AR, but not β1AR, activates a Gi-Gβγ-PI3K-Akt cell survival signaling pathway6,9, and inhibition of this pathway abolishes the ability of β2AR to block hypoxia- and ROS-induced myocyte apoptosis.6 Thus, the β2AR-Gi- Gβγ-PI3K-Akt signaling cascade not only counteracts βAR-induced apoptosis and but also protects cardiomyocytes against other apoptotic stimuli.The “ Bad” or “Ugly”: β2AR-coupled Gi Negates β1AR- and β2AR-Mediated Contractile Support in the Failing HeartAlthough beneficial in terms of cardiac protection, the β2AR protective effect comes at the cost of compromised contractile support. Previous studies have demonstrated that the β2AR-Gi functionally restricts the β2AR-Gs–mediated cAMP/PKA signaling to subsarcolemmal microdomain in the vicinity of L-type Ca2+ channels, thus preventing the Gs-PKA mediated phosphorylation of some key target proteins in SR membrane and intracellular contractile myofilaments, blunting the positive inotropic and lusitropic effects.10–13 Activation of PI3K, an important downstream event of the β2AR-Gi signaling, confines and minimizes the concurrent β2AR-Gs–evoked cAMP/PKA signaling.14 In the failing heart, an upregulation of Gi15 and a selective downregulation of β1AR16 are often associated with enhanced β2AR-Gi signaling and reduced myocardial contractile response to both β1AR and β2AR stimulation. Importantly, inhibition of the Gi signaling pathway with PTX restores the diminished βAR inotropic response in a variety of heart failure models, including a spontaneous hypertensive rat heart failure model,17 a myocardial infarction rat heart failure model,18 and myocytes from failing human hearts.19 Furthermore, in failing porcine and mouse hearts or cardiomyocytes, inhibition of βAR-targeted PI3K, the major downstream mediator the Gi signaling, improves the contractile function of the failing myocardium.20,21 Now, He and colleagues demonstrate a cross-inhibition of β1AR-mediated stimulation of ICa,L by the β2AR-Gi signaling.3 Similarly, the β2AR-Gi signaling largely inhibits β1AR-induced positive inotropic effect in adult rat cardiomyocytes moderately overexpressing Na+/Ca2+ exchanger proteins.22 Collectively, these studies suggest that reinforcement of β2AR-Gi signaling is a hallmark of the failing heart and is critically involved in heart failure–associated dysfunction or desensitization of both βAR subtypes.The Cell Logic of Multifaceted β2AR-Gi SignalingAt the first glance, inhibition of the β1AR-mediated stimulation of ICa,L and, consequentially, the contractile response by β2AR-coupled Gi might paint β2AR stimulation as the “bad guy” in the context of heart failure. It is, however, noteworthy that sustained β1AR stimulation induces myocyte apoptosis and positive inotropic effect mainly via PKA-independent stimulation of L-type Ca2+ channels and resultant activation of CaMKII in adult mouse and rat cardiomyocytes (Figure).23,24 Inhibition of ICa,L or CaMKII can effectively protect the cultured cardiomyocytes from β1AR-induced apoptotic death.23 In contrast, overexpression of the L-type channel (α1C) causes severe cardiac hypertrophy and apoptosis.25 Recent in vivo studies have further confirmed that inhibition of CaMKII substantially prevents cardiac maladaptive remodeling from excessive βAR stimulation and myocardial infarction and markedly improves cardiac function (Figure).26 In light of these observations, we envision that the inhibitory effect of the β2AR-Gi signaling on β1AR-mediated activation of ICa,L and resultant CaMKII may represent an intrinsic cardiac protective mechanism, acting as a “friend” rather than a “foe,” to protect the heart against apoptosis and maladaptive remodeling in response to chronic catecholamine stimulation. Thus, the apparent “bad” or “ugly” behavior might be an overreaction of the defense mechanism; appropriately tipping the balance might be able to bring out the “good” nature of β2AR-Gi signaling to benefit the struggling heart.Potential Mechanisms Underlying the Gi-Dependent Crosstalk of βAR SubtypesThe exact mechanism underlying the cross-inhibition of β1AR function by the β2AR-Gi signaling remains elusive. There are several candidate mechanisms, including the β2AR-Gi signaling–mediated direct suppression of adenylyl cyclase activity or activation of PI3K. With respect to the latter, it has been shown that activation of PI3K inhibits ICa,L in normal adult rat cardiomyocytes.27 More importantly, inhibition of membrane-targeted PI3K activity ameliorates cardiac dysfunction and improves survival in multiple heart failure models.20,21Alternatively, we have recently demonstrated that β1AR and β2AR are able to form heterodimers in adult mouse cardiomyocytes and HEK 293 cells.28,29 Specifically, in cardiomyocytes, the heterodimeric receptors exhibit altered ligand binding profiles, enhanced signaling efficiency in regulating myocyte cAMP production and contractility, and suppressed β2AR spontaneous activity in the absence of agonist stimulation, thus optimizing β-adrenergic regulation of cardiac contractility (Figure).28 Interestingly, heterodimerization between β1AR and β2AR inhibits the agonist-promoted internalization of β2AR and its ability to activate the Gi-ERK1/2 MAPK signaling pathway in HEK 293 cells.29 Similarly, whereas either β2AR or β3AR alone couples to both Gs and Gi proteins, the β2AR-β3AR heterodimer is unable to activate Gi signaling.30 Thus, alterations in the status of oligomerization of GPCRs from the same or different families may lead to changes in the selectivity and specificity of G protein coupling of those receptors, thereby altering their signaling and functional features, perhaps also raising important therapeutic considerations.The heart failure–associated decrease in the ratio of β1AR to β2AR,3,16 in conjunction with changes in cardiomyocyte morphology and membrane integrity, might interfere with the heterodimerization of the remaining βARs, thus allowing the β2AR to better couple to Gi proteins. The enhanced Gi signaling inhibits β1AR-mediated increases in ICa,L and contractility, perhaps most importantly, ameliorates β1AR-evoked maladaptive remodeling and loss of cardiomyocytes (Figure). These hypotheses merit future investigation.In summary, it is reasonable to speculate that the selective downregulation of β1AR and the upregulation of β2AR-coupled Gi signaling in the functionally compensated hypertrophied heart may represent salutary cardiac adaptation, which may protect myocytes against apoptosis and maladaptive remodeling and consequently slow the progression of cardiomyopathy and contractile dysfunction. However, exaggerated β2AR-Gi signaling blunts the Gs-mediated stimulation of ICa,L and contractile support, thus contributing to the contractile defect of the failing heart despite of its antiapoptotic effect. Thus, restoration of the Yin and Yang balance of β2AR-coupled Gi and Gs signaling cascades may open a novel therapeutic avenue for the treatment of heart failure.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.This work is supported by National Institutes of Health intramural research grant (to Z.W.Z., X.Z., and R.P.X.), and in part by Chinese National Key Project 973 (G2000056906) and Chinese Young Investigator Award (30225036). The authors thank Dr H. Cheng for critical comments and discussions.FootnotesCorrespondence to Rui-Ping Xiao, MD, PhD, Laboratory of Cardiovascular Science, Gerontology Research Center, NIA, NIH, 5600 Nathan Shock Drive, Baltimore, MD 21224. E-mail [email protected] References 1 Lands AM, Arnold A, Mcauliff JP, Luduena FP, Brown TG. Differentiation of receptor systems activated by sympathomimetic amines. Nature. 1967; 214: 596–598.Google Scholar2 Xiao RP, Zhu W, Zheng M, Bond R, Lakatta EG, Cheng H. Subtype-specific β-adrenergic signaling pathways and their clinical implications. Trends Pharmacol Sci. 2004; 25: 358–365.CrossrefMedlineGoogle Scholar3 He JQ, Balijepalli RC, Haworth RA, Kamp TJ. Crosstalk of β-adrenergic receptor subtypes through Gi blunts β-adrenergic stimulation of L-type Ca2+ channels in canine heart failure. Circ Res. 2005; 97: 566–573.LinkGoogle Scholar4 Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of β1- and β2-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation. 1999; 100: 2210–2212.CrossrefMedlineGoogle Scholar5 Zaugg M, Xu W, Lucchinetti E, Shafiq SA, Jamali NZ, Siddiqui MA. β-adrenergic receptor subtypes differentially affect apoptosis in adult rat ventricular myocytes. Circulation. 2000; 102: 344–350.CrossrefMedlineGoogle Scholar6 Chesley A, Ohtani S, Asai T, Xiao RP, Lunberg MS, Lakatta EG, Crow MT. The β2-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through Gi-dependent coupling to phosphatidylinositol 3′-kinase. Circ Res. 2000; 87: 1172–1179.CrossrefMedlineGoogle Scholar7 Patterson AJ, Zhu W, Chow A, Agrawal R, Kosek J, Xiao RP, Kobilka B. Protecting the myocardium: a role for the β2-adrenergic receptor in the heart. Crit Care Med. 2004; 32: 1041–1048.CrossrefMedlineGoogle Scholar8 Ahmet I, Krawczyk M, Heller P, Moon C, Lakatta EG, Talan MI. Beneficial effects of chronic pharmacological manipulation of β-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation. 2004; 110: 1083–1090.LinkGoogle Scholar9 Zhu WZ, Zheng M, Lefkowitz RJ, Koch WJ, Kobilka B, Xiao RP. Dual modulation of cell survival and cell death by β2-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci U S A. 2001; 98: 1607–1612.CrossrefMedlineGoogle Scholar10 Kuschel M, Zhou YY, Cheng H, Zhang SJ, Chen-Izu Y, Lakatta EG, Xiao RP. Gi protein-mediated functional compartmentalization of cardiac β2-adrenergic signaling. J Biol Chem. 1999; 274: 22048–22052.CrossrefMedlineGoogle Scholar11 Chen-Izu Y, Xiao RP, Izu LT, Cheng H, Kuschel M, Spurgeon H, Lakatta EG. Gi-dependent localization of β2-adrenergic receptor signaling to L-type Ca2+ channels. Biophys J. 2000; 79: 2547–2556.CrossrefMedlineGoogle Scholar12 Xiao RP, Ji X, Lakatta EG. Functional coupling of the β2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol. 1995; 47: 322–329.MedlineGoogle Scholar13 Xiao RP, Avdonin P, Zhou YY, Cheng H, Akhter SA, Eschenhagen T, Lefkowitz RJ, Koch WJ, Lakatta EG. Coupling of β2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Circ Res. 1999; 84: 43–52.CrossrefMedlineGoogle Scholar14 Jo SH, Leblais V, Wang PH, Crow MT, Xiao RP. Phosphatidylinositol 3-kinase functionally compartmentalizes the concurrent Gs signaling during β2-adrenergic stimulation. Circ Res. 2002; 91: 46–53.LinkGoogle Scholar15 Eschenhagen T, Mende U, Nose M, Schmitz W, Scholz H, Haverich A, Hirt S, Doring V, Kalmar P, Hoppner W. Increased messenger RNA level of the inhibitory G protein alpha subunit Gia1 in human end-stage heart failure. Circ Res. 1992; 70: 688–696.CrossrefMedlineGoogle Scholar16 Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S. β1- and β2-adrenergic receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective β1-receptor down-regulation in heart failure. Circ Res. 1986; 59: 297–309.LinkGoogle Scholar17 Xiao RP, Zhang SJ, Chakir K, Avdonin P, Zhu W, Bond RA, Balke CW, Lakatta EG, Cheng H. Enhanced Gi signaling mediates the diminution of β2-adrenergic contractile response in failing spontaneous hypertensive rat heart. Circulation. 2003; 108: 1633–1639.LinkGoogle Scholar18 Kompa AR, Gu XH, Evans BA, Summers RJ. Desensitization of cardiac β-adrenoceptor signaling with heart failure produced by myocardial infarction in the rat. Evidence for the role of Gi but not Gs or phosphorylating proteins. J Mol Cell Cardiol. 1999; 31: 1185–1201.CrossrefMedlineGoogle Scholar19 Brown LA, Harding SE. The effect of pertussis toxin on β-adrenoceptor responses in isolated cardiac myocytes from noradrenaline-treated guinea-pigs and patients with cardiac failure. Br J Pharmacol. 1992; 106: 115–122.CrossrefMedlineGoogle Scholar20 Perrino C, Naga Prasad SV, Schroder JN, Hata JA, Milano C, Rockman HA. Restoration of β-adrenergic receptor signaling and contractile function in heart failure by disruption of the βARK1/phosphoinositide 3-kinase complex. Circulation. 2005; 111: 2579–2587.LinkGoogle Scholar21 Perrino C, Naga Prasad SV, Patel M, Wolf MJ, Rockman HA. Targeted inhibition of β-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves β-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression. J Am Coll Cardiol. 2005; 45: 1862–1870.CrossrefMedlineGoogle Scholar22 Sato M, Gong H, Terracciano CMN, Ranu H, Harding SE. Loss of β-adrenoceptor response in myocytes overexpressing the Na+/Ca2+-exchanger. J Mol Cell Cardiol. 2004; 36: 43–48.CrossrefMedlineGoogle Scholar23 Zhu WZ, Wang SQ, Chakir K, Kolbilka BK, Cheng H, Xiao RP. Linkage of β1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/Calmodulin Kinase II. J Clin Invest. 2003; 111: 617–625.CrossrefMedlineGoogle Scholar24 Wang W, Zhu W, Wang S, Yang D, Crow MT, Xiao RP, Cheng H. Sustained β1-adrenergic stimulation modulates cardiac contractility by Ca2+/calmodulin kinase signaling pathway. Circ Res. 2004; 95: 798–806.LinkGoogle Scholar25 Muth JN, Bodi I, Lewis W, Varadi G, Schwartz A. A Ca2+-dependent transgenic model of cardiac hypertrophy: A role for protein kinase Calpha. Circulation. 2001; 103: 140–147.CrossrefMedlineGoogle Scholar26 Zhang R, Khoo MSC, Wu Y, Yang Y, Grueter CE, Ni G, Price EE Jr, Thiel W, Guatimosim S, Song LS, Madu EC, Shah AN, Vishnivetskaya TA, Atkinson JB, Gurevich VV, Salama G, Lederer WJ, Colbran RJ, Anderson ME. Calmodulin kinase II inhibition protects against structural heart disease. Nature Medicine. 2005; 11: 409–417.CrossrefMedlineGoogle Scholar27 Leblais V, Jo SH, Chakir K, Maltsev V, Zheng M, Crow MT, Wang W, Lakatta EG, Xiao RP. Phosphatidylinositol 3-kinase offsets cAMP-mediated positive inotropic effect via inhibiting Ca2+ influx in cardiomyocytes. Circ Res. 2004; 95: 1183–1190.LinkGoogle Scholar28 Zhu WZ, Chakir K, Zhang S, Yang D, Lavoie C, Bouvier M, Hébert TE, Lakatta EG, Cheng H, Xiao RP. Heterodimerization of β1- and β2-adrenergic receptor subtypes optimizes β-adrenergic modulation of cardiac contractility. Circ Res. 2005; 97: 244–251.LinkGoogle Scholar29 Lavoie C, Mercier JF, Salahpour A, Umapathy D, Breit A, Villeneuve LR, Zhu WZ, Xiao RP, Lakatta EG, Bouvier M, Hebert TE. β1/β2-adrenergic receptor heterodimerization regulates β2-adrenergic receptor internalization and ERK signaling efficacy. J Biol Chem. 2002; 277: 35402–35410.CrossrefMedlineGoogle Scholar30 Breit A, Lagace M, Bouvier M. Hetero-oligomerization between β2- and β3-adrenergic receptors generates a β-adrenergic signaling unit with distinct functional properties. J Biol Chem. 2004; 279: 28756–28765.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Liu Z, Tao B, Fan S, Cui S, Pu Y, Qiu L, Xia H and Xu L (2020) Over-expression of microRNA-145 drives alterations in β-adrenergic signaling and attenuates cardiac remodeling in heart failure post myocardial infarction, Aging, 10.18632/aging.103320, 12:12, (11603-11622), Online publication date: 18-Jun-2020. Lukasheva V, Devost D, Le Gouill C, Namkung Y, Martin R, Longpré J, Amraei M, Shinjo Y, Hogue M, Lagacé M, Breton B, Aoki J, Tanny J, Laporte S, Pineyro G, Inoue A, Bouvier M and Hébert T (2020) Signal profiling of the β1AR reveals coupling to novel signalling pathways and distinct phenotypic responses mediated by β1AR and β2AR, Scientific Reports, 10.1038/s41598-020-65636-3, 10:1 Xu X and Wang D (2020) The progress and controversial of the use of beta blockers in patients with heart failure with a preserved ejection fraction, IJC Heart & Vasculature, 10.1016/j.ijcha.2019.100451, 26, (100451), Online publication date: 1-Feb-2020. Chu S, Peng F, Wang J, Liu L, Meng L, Zhao J, Han X and Ding W (2020) Catestatin in defense of oxidative-stress-induced apoptosis: A novel mechanism by activating the beta2 adrenergic receptor and PKB/Akt pathway in ischemic-reperfused myocardium, Peptides, 10.1016/j.peptides.2019.170200, 123, (170200), Online publication date: 1-Jan-2020. Kayki-Mutlu G, Karaomerlioglu I, Arioglu-Inan E and Altan V (2019) Beta-3 adrenoceptors: A potential therapeutic target for heart disease, European Journal of Pharmacology, 10.1016/j.ejphar.2019.172468, 858, (172468), Online publication date: 1-Sep-2019. Woo A, Ge X, Pan L, Xing G, Mo Y, Xing R, Li X, Zhang Y, Wainer I, Cheng M and Xiao R (2019) Discovery of β-arrestin-biased β2-adrenoceptor agonists from 2-amino-2-phenylethanol derivatives, Acta Pharmacologica Sinica, 10.1038/s41401-018-0200-x, 40:8, (1095-1105), Online publication date: 1-Aug-2019. Cook R, Bussey C, Fomison‐Nurse I, Hughes G, Bahn A, Cragg P and Lamberts R (2019) β 2 ‐Adrenoceptors indirectly support impaired β 1 ‐adrenoceptor responsiveness in the isolated type 2 diabetic rat heart , Experimental Physiology, 10.1113/EP087437, 104:6, (808-818), Online publication date: 1-Jun-2019. Strohman M, Maeda S, Hilger D, Masureel M, Du Y and Kobilka B (2019) Local membrane charge regulates β2 adrenergic receptor coupling to Gi3, Nature Communications, 10.1038/s41467-019-10108-0, 10:1 Huang J, Li C, Song Y, Fan X, You L, Tan L, Xiao L, Li Q, Ruan G, Hu S, Cui W, Li Z, Ni L, Chen C, Woo A, Xiao R and Wang D (2018) ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure, Cell Discovery, 10.1038/s41421-018-0058-6, 4:1 Bernstein D (2018) Cardiovascular Receptors and Signaling in Heart Failure Heart Failure in the Child and Young Adult, 10.1016/B978-0-12-802393-8.00002-8, (21-31), . Spadari R, Cavadas C, de Carvalho A, Ortolani D, de Moura A and Vassalo P (2017) Role of Beta-adrenergic Receptors and Sirtuin Signaling in the Heart During Aging, Heart Failure, and Adaptation to Stress, Cellular and Molecular Neurobiology, 10.1007/s10571-017-0557-2, 38:1, (109-120), Online publication date: 1-Jan-2018. Nakib I, Martin-Eauclaire M and Laraba-Djebari F (2016) Involvement of Cholinergic and Adrenergic Receptors in Pathogenesis and Inflammatory Response Induced by Alpha-Neurotoxin Bot III of Scorpion Venom, Inflammation, 10.1007/s10753-016-0401-8, 39:5, (1670-1680), Online publication date: 1-Oct-2016. Woo A, Song Y, Xiao R and Zhu W (2014) Biased β 2 -adrenoceptor signalling in heart failure: pathophysiology and drug discovery , British Journal of Pharmacology, 10.1111/bph.12965, 172:23, (5444-5456), Online publication date: 1-Dec-2015. Montó F, Oliver E, Vicente D, Buendía F, Rueda J, Agüero J, Almenar L, Valldecabres C, Rovira E, Muedra V, Noguera M, Ivorra M and DʼOcon P (2015) β2- and β1-Adrenoceptor Expression Exhibits a Common Regulatory Pattern With GRK2 and GRK5 in Human and Animal Models of Cardiovascular Diseases, Journal of Cardiovascular Pharmacology, 10.1097/FJC.0000000000000299, 66:5, (478-486), Online publication date: 1-Nov-2015. Odnoshivkina U, Sytchev V, Nurullin L, Giniatullin A, Zefirov A and Petrov A (2015) β2-adrenoceptor agonist-evoked reactive oxygen species generation in mouse atria: implication in delayed inotropic effect, European Journal of Pharmacology, 10.1016/j.ejphar.2015.08.020, 765, (140-153), Online publication date: 1-Oct-2015. Hattori Y, Hattori K and Suzuki T (2015) Differential Modulation of Cardiac Sympathetic Neural Control and β-Adrenoceptor–G Protein Signaling Cascade in Rats With Type 1 and Type 2 Diabetes, Diabetes, 10.2337/db15-0503, 64:8, (2708-2710), Online publication date: 1-Aug-2015. Soriano-Ursúa M, Trujillo-Ferrara J, Arias-Montaño J and Villalobos-Molina R (2015) Insights into a defined secondary binding region on β-adrenoceptors and putative roles in ligand binding and drug design, MedChemComm, 10.1039/C5MD00011D, 6:6, (991-1002) Lu C, Sun Z and Wang L (2015) Inhibition of L-type Ca2+ current by ginsenoside Rd in rat ventricular myocytes, Journal of Ginseng Research, 10.1016/j.jgr.2014.11.003, 39:2, (169-177), Online publication date: 1-Apr-2015. Nyman E, Lindgren I, Lövfors W, Lundengård K, Cervin I, Sjöström T, Altimiras J and Cedersund G (2015) Mathematical modeling improves EC 50 estimations from classical dose-response curves , FEBS Journal, 10.1111/febs.13194, 282:5, (951-962), Online publication date: 1-Mar-2015. Reinartz M, Kälble S, Littmann T, Ozawa T, Dove S, Kaever V, Wainer I and Seifert R (2014) Structure-bias relationships for fenoterol stereoisomers in six molecular and cellular assays at the β2-adrenoceptor, Naunyn-Schmiedeberg's Archives of Pharmacology, 10.1007/s00210-014-1054-5, 388:1, (51-65), Online publication date: 1-Jan-2015. Melsom C, Hussain R, Ørstavik Ø, Aronsen J, Sjaastad I, Skomedal T, Osnes J, Levy F and Krobert K (2014) Non-classical regulation of β1- and β2-adrenoceptor-mediated inotropic responses in rat heart ventricle by the G protein Gi, Naunyn-Schmiedeberg's Archives of Pharmacology, 10.1007/s00210-014-1036-7, 387:12, (1177-1186), Online publication date: 1-Dec-2014. Yang J, Liu Y, Fan X, Li Z and Cheng Y (2013) A pathway and network review on beta-adrenoceptor signaling and beta blockers in cardiac remodeling, Heart Failure Reviews, 10.1007/s10741-013-9417-4, 19:6, (799-814), Online publication date: 1-Nov-2014. Bosier B and Hermans E (2014) Promises of Biased Signaling in the Development of Improved Therapeutics Biased Signaling in Physiology, Pharmacology and Therapeutics, 10.1016/B978-0-12-411460-9.00008-2, (251-292), . Salazar N, Vallejos X, Siryk A, Rengo G, Cannavo A, Liccardo D, De Lucia C, Gao E, Leosco D, Koch W and Lymperopoulos A (2013) GRK2 blockade with βARKct is essential for cardiac β2-adrenergic receptor signaling towards increased contractility, Cell Communication and Signaling, 10.1186/1478-811X-11-64, 11:1, Online publication date: 1-Dec-2013. Soriano-Ursúa M, Trujillo-Ferrara J, Correa-Basurto J and Vilar S (2013) Recent Structural Advances of β1 and β2 Adrenoceptors Yield Keys for Ligand Recognition and Drug Design, Journal of Medicinal Chemistry, 10.1021/jm400471z, 56:21, (8207-8223), Online publication date: 14-Nov-2013. Fajardo G, Zhao M, Urashima T, Farahani S, Hu D, Reddy S and Bernstein D (2013) Deletion of the β2-adrenergic receptor prevents the development of cardiomyopathy in mice, Journal of Molecular and Cellular Cardiology, 10.1016/j.yjmcc.2013.07.016, 63, (155-164), Online publication date: 1-Oct-2013. Pérez-Schindler J, Philp A and Hernandez-Cascales J (2013) Pathophysiological relevance of the cardiac β2-adrenergic receptor and its potential as a therapeutic target to improve cardiac function, European Journal of Pharmacology, 10.1016/j.ejphar.2012.11.001, 698:1-3, (39-47), Online publication date: 1-Jan-2013. van Deursen C, van Middendorp L and Prinzen F (2013) Dyssynchronous Heart Failure: From Bench to Bedside Translational Approach to Heart Failure, 10.1007/978-1-4614-7